is actively involved in T cell exhaustion. TIME is comprised of various stromal cells, extracellular matrix (ECM), innate and adaptive immune cells, (such as, cancer-associated fibroblasts (CAFs), tumor-associated macrophages (TAMs), tumor-associated neutrophils (TANs), and dendritic cells (DCs)), abnormal blood and lymphatic vessels, acidic pH, hypoxia, and high interstitial fluid pressure, that contribute to stunting antitumor immune response. [2] Moreover, immune checkpoints and negative regulatory pathways, for example, programmed cell death receptor 1 (PD1) and its ligand (PD-L1), indoleamine 2,3-dioxygenase 1 (IDO-1), cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and transforming growth factor β (TGF-β) are the main culprits in TIME that promote T cell exhaustion and adaptive resistance. [3] The considerable level of interplay, complicity, and crosstalk between tumor and immune cells further adds complexity to TIME. A deeper understanding of TIME, however, is urgently needed to deal with the key mechanisms underlying the ability of TIME to evade antitumor immunity.The failure of current immunotherapeutics, such as, antibodies, immune checkpoint inhibitors, cytokines, and agonists, to target the TIME because of its complex milieu leads to tumor progression and metastasis. Preclinical and clinical studies suggest that therapeutic drugs drive cascades of systemic toxicityThe tumor immune microenvironment (TIME) is comprised of a complex milieu that contributes to stunting antitumor immune responses by restricting T cells to accumulate in the vicinity of the tumor. Nanomedicinebased strategies are being proposed as a salvage effort to reinvigorate antitumor immunity. Various strategies, however, often fail to unleash the antitumor immune response because of the paucity of appropriate therapeutic targets in the complex TIME, invigorating a fervor of investigation into mechanisms underlying the TIME to resist nanomedicines. In this review article, effective nano/biomaterial-based delivery and TIME normalization approaches that promote T cell-mediated antitumor immune response will be discussed, with a focus on emerging preclinical and clinical strategies for immune normalization. Based on currently available evidence, it seems as if the ultimate success of cancer immunotherapy and nanomedicine hinges on the capacity to normalize the TIME. Here, how nanomedicines target immunosuppressive cells and signaling pathways to broaden the impact of cancer immunotherapy are explored. Acquisition of the urgently needed knowledge of nanomedicine-mediated immune normalization will guide researchers and scientists towards clinical applications of cancer immunotherapy.